Oral VK2735
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
Viking Therapeutics · Phase 2 · Completed · Enrollment 280
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebo Assignment | n/r | n/r | n/r | n/r |
| Active Assignment (Dose #1) | n/r | n/r | n/r | n/r |
| Active Assignment (Dose #2) | n/r | n/r | n/r | n/r |
| Active Assignment (Dose #3) | n/r | n/r | n/r | n/r |
| Active Assignment (Dose #4) | n/r | n/r | n/r | n/r |
| Active Assignment (Dose #5) | n/r | n/r | n/r | n/r |
| Active Assignment (Dose #6) | n/r | n/r | n/r | n/r |
Not shown
- Placebo Assignment: endpoint not reported
- Active Assignment (Dose #1): endpoint not reported
- Active Assignment (Dose #2): endpoint not reported
- Active Assignment (Dose #3): endpoint not reported
- Active Assignment (Dose #4): endpoint not reported
- Active Assignment (Dose #5): endpoint not reported
- Active Assignment (Dose #6): endpoint not reported